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Serotonin (5-HT) is widely implicated as a key neurotransmitter relevant to a range of
psychiatric disorders and psychological processes. The role of central nervous 5-HT
function underlying these processes can be examined through serotonergic challenge
methodologies. Acute tryptophan depletion (ATD) is a key challenge method whereby a
diminished dietary intake of tryptophan—the amino acid precursor to brain 5-HT synthesis
—results in temporary diminished central nervous 5-HT synthesis. While this particular
methodology has been used in adult populations, it was only recently that modifications
were made to enable the use of ATD in child and adolescent populations. Additionally, the
Moja-De modification of the ATD challenge methodology has demonstrated benefits over
other ATD techniques used previously. The aim of this protocol paper is to describe the
ATD Moja-De methodology in detail, its benefits, as well as studies that have been
conducted to validate the procedure in child and adolescent samples. The ATD Moja-De
protocol provides a potential methodology for investigating the role of central nervous 5-
HT via manipulation of brain tryptophan availability in human psychopathology from a
developmental viewpoint.
Keywords: acute tryptophan depletion, ATD, Moja-De, central nervous 5-HT, serotonin challenge procedure, ATD
Moja-De in child and adolescent populations, attention deficit hyperactivity disorderINTRODUCTION
Serotonin (5-HT) is a neurotransmitter that is involved in a variety of psychiatric disorders, such as
depressive disorders, anxiety disorders, and attention deficit hyperactivity disorder (ADHD).
ADHD is a highly prevalent psychiatric disorder. Recent research has shown that, apart from
changes in central nervous dopaminergic activity as well as other neurotransmitter systems (1) the
underlying neurobiology of ADHD as a disorder is also subject to changes in 5-HT
neurotransmission (2–9). Research on the role of the amino acid (AA) tryptophan (TRP, theg March 2020 | Volume 10 | Article 10071
Stewart et al. Investigating Central Nervous 5HT Functionphysiological precursor of 5-HT) and related brain 5-HT
synthesis) have used acute tryptophan depletion (ATD). ATD
is a physiological serotonergic challenge procedure that has been
widely used over the last decade to investigate the role of 5-HT in
a variety of disorders, in both children and adolescents (10, 11),
and adults (9, 12). Additionally, ATD allows investigations into
the role of 5-HT on various behavioral and cognitive processes.
ATD is a safe, transient method of reducing brain 5-HT synthesis
by both reducing the central nervous availability of the 5-HT
precursor AA TRP and increasing competition for the active
transport mechanism that delivers TRP into the brain. In
addition, the AAs administered stimulate protein synthesis in
the liver, thereby taking TRP from plasma stores and
subsequently contributing to the depletion or diminished
availability of TRP across the blood brain barrier (BBB). These
effects are temporary and are quickly reversed by resumption of a
normal diet with adequate levels of TRP. Historically, several
ATD protocols have been used since the technique was first
applied in humans in 1977, and these methods have included a
varying number and/or amount of AAs (13, 14). Until recently,
however, there had been no safe and effective short-term
neurochemical challenge procedure available to deplete brain
5-HT synthesis in young people, such as children
and adolescents.
The more recent development of a new modification of an
ATD procedure allows for this particular ATD protocol to be
administered to children and adolescents in a safe and effective
manner. This new body weight adapted ATD protocol is named
Moja-De (a modification of the ATD protocol by Moja and
colleagues), and it indirectly accounts for baseline levels of the 5-
HT-precursor AA TRP because baseline TRP was shown to be
correlated with body weight (15). This new technique therefore
allows investigation of the effects of a short-term decrease in
brain 5-HT synthesis in young people.
Acute Tryptophan Depletion and the
Development of the Moja-De Protocol
ATD is based on the premise that the depletion of TRP, the
physiological precursor AA of central nervous 5-HT synthesis,
leads to depletion of central nervous 5-HT. TRP is an essential
AA that mammals cannot synthesize and must be acquired from
dietary sources. Dietary TRP can be directly used by the gut
microbiota to synthesize ligands, kynurenine via the kynurenine
pathway or peripheral 5-HT through TRP hydroxylase 1 enzyme in
the enterochromaffin cells of the gastric mucosa. Thus, gut
microbiota can serve as important modulators of TRP availability
(4). Plasma TRP levels are influenced by the balance between the
dietary intake of TRP and its removal from the plasma by protein
synthesis. Most of the TRP in plasma is bound to albumin. Under
normal physiological conditions the free TRP portion accounts for
10-15% of total TRP as shown by more recent research (16). The
free TRP portion is available for transport into the central nervous
system (CNS). Hence, central nervous TRP availability may bemore
accurately predicted by free TRP than total (free + protein bound)
TRP plasma levels. TRP is transported across the BBB by an active
transporter (L1), at which TRP and all other large neutral AAsFrontiers in Psychiatry | www.frontiersin.org 2(LNAAs: e.g., valine, leucine, isoleucine, methionine, phenylalanine,
and tyrosine) also compete. Once in the brain, TRP is converted
into 5-hydroxytryptophan (5-HTP) by the enzyme TRP
hydroxylase 2 (the rate-limiting enzyme of central nervous 5-HT
synthesis). 5-HTP is then decarboxylated by the enzyme aromatic
acid decarboxylase to 5-HT.
There are three factors that are important in determining the
rate of brain 5-HT synthesis, and thus three points at which brain
5-HT synthesis may be influenced. These three factors include:
(1) The concentration of free TRP in the plasma, which is
dependent on dietary intake and/or restriction of TRP, (2) the
amount of free TRP that is able to cross the BBB via competition
for the LNAA transporter with other AAs, (3) the inhibition of
th e TRP hydroxy l a s e 2 enzyme , [ e . g . , b y pa r a -
chlorophenylalanine (PCPA); a rate limiting enzyme for TRP
hydroxylase 2, which therefore impacts on central 5-HT
synthesis). Central nervous 5-HT synthesis can be influenced
by interfering with any or all of these factors. However, the best
ATD results in humans with regards to depletion magnitude
were achieved using a combination of dietary restriction (point
1), and viamethods to reduce competitive binding of TRP via the
LNAA transporter and across the BBB (point 2). Consequently,
the ATD technique uses a combination of a low TRP diet and a
TRP-deficient protein load containing large amounts of the other
LNAAs to produce maximal central nervous TRP depletion (i.e.,
the administered AAs compete with endogenous TRP on the
uptake into the brain over the BBB). A further mechanism that
impacts brain TRP availability in the brain is passive diffusion, in
both directions, across the BBB. However, this particular
mechanism only contributes to a rather small degree (17–19).
The 7-amino-acid ATD mixture as described by Moja et al.
(20), was associated with a marked reduction in plasma TRP
levels. This protocol was later modified for administration to
young people (coined Moja-De, with “De” being related to the
last name of Professor Lothar Demisch who suggested and
developed this ATD modification) with a body-weight-adapted
dosing scheme, and a lower amount of methionine relative to
conventional mixtures. The reduction in methionine was to
reduce unwanted side effects, such as vomiting and nausea,
that were frequently observed in adult populations using
alternative formulations (21).
The ATD Moja-De protocol administers AA within an
aqueous suspension, in which the relevant AA quantities are
dosed in accordance with the participants’ body weights. The AA
quantities of the ATDMoja-De beverage are (dosage per 10 kg of
body weight): L-phenylalanine (PHE 1.32 g), L-leucine (LEU
1.32 g), L-isoleucine (ILE 0.84 g), L-methionine (MET 0.5 g), L-
valine (VAL 0.96 g), L-threonine (THR 0.6 g), and L-lysine (LYS
0.96 g). The TRP Balanced Control (BAL) beverage contains the
same AA quantities with an additional 0.7 g of L-TRP per 10 kg
of body weight. The chemical properties and descriptions of the
eight AAs used as part of the ATD Moja-De and the BAL
protocol are summarized in Table 1. Table 1 additionally
shows the AAs that comprise the ATD Moja-De mixture (AAs
1 to 7) as well as the amounts of each AA in grams per 10 kg of
body weight, as per the body weight adapted protocol. The finalMarch 2020 | Volume 10 | Article 1007
TABLE 1 | Chemical properties and descriptions of the AAs and amounts (grams/10kg body weight) that make up the ATD Moja-De and BAL mixture and a brief description regarding manufacturing, packaging and
nine
H
(7) L-Lysine (LYS) (8) L-Tryptophan
(TRP)
C6H14N2O2 C11H12N2O2
146.19 g/mol 204.23 g/mol
e (7) L-Lysine (LYS) (8) L-Tryptophan
(TRP)
Yes No
Yes Yes
body 0.96 g/10 kg of
body weight
BAL only 0.7 g/10
kg of body weight
g bject* 7.7 g/80 kg subject* BAL only 5.6 g/80
kg subject*
m 7.7 g/200 mL
suspension
BAL only 5.6 g/200
mL
ed above/80 kg subject* to 200 mL with SyrSpend®
v Each subject receives a proportional amount of ATD
mL of water within an aqueous suspension
weight.
roprietary processing steps. As an example for such
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Amino acid
chemical
name
(1) L-Phenylalanine
(PHE)
(2) L-Leucine (LEU) (3) L-Isoleucine (ILE) (4) L-Methionine
(MET)
(5) L-Valine (VAL) (6) L-T
(T
Chemical
Structure
Molecular
formula
C9H11NO2 C6H13NO2 C6H13NO2 C5H11NO2S C5H11NO2 C4H9NO3
Molecular
Weight
165.19 g/mol 131.17 g/mol 131.17 g/mol 149.21 g/mol 117.15 g/mol 119.12 g/m
(1) L-Phenylalanine
(PHE)
(2) L-Leucine (LEU) (3) L-Isoleucine (ILE) (4) L-Methionine
(MET)
(5) L-Valine (VAL) (6) L-Thre
(THR)
ATD (acute
tryptophan
depletion
beverage)→
amino acids 1-
7
Yes Yes Yes Yes Yes Yes
BAL (TRP
balanced
control
beverage)→
amino acids 1-
8
Yes Yes Yes Yes Yes Yes
Weight
adapted ATD/
BAL protocol
1.32 g/10 kg of body
weight
1.32 g/10 kg of body
weight
0.84 g/10 kg of body
weight
0.5 g/10 kg of
body weight
0.96 g/10 kg of body
weight
0.6 g/10 k
weight
Weight/80 kg
child or
adolescent
10.6 g/80 kg subject* 10.6 g/80 kg subject* 6.7 g/80 kg subject* 4.0 g/80 kg
subject*
7.7 g/80 kg subject* 4.8 g/80 k
Formulation→
all amino acids
are made up to
200 mL with
SyrSpend®
10.6 g/200 mL
suspension
10.6 g/200 mL
suspension
6.7 g/200 mL
suspension
4.0 g/200 mL
suspension
7.7 g/200 mL
suspension
4.8 g/200
suspensio
The ATD beverage is made up of the 7 AA (for the ATD aqueous suspension) amounts, and 8 AA (for the BAL aqueous suspension) amoun
SF (Purified Water, Modified Food Starch, Sodium Citrate, Citric Acid, Malic Acid, Sodium Benzoate, Sucralose, Simethicone, and Cherry Fla
AAs according to the individual body weight. All body weight adapted dosing steps can be delivered in a beverage of proportional volume o
depending on body weight (see Tab. 6). For example, a 40 kg subject can receive 100 mL with the respective AAs related to the individual b
Manufacture
process
An example of a possible manufacture process for the ATD/BAL protocols include the AAs being manufactured and purified through a series
processing steps, in a study currently underway (22) these steps have been validated and performed in accordance with GMP under license
77099.
ATD/BAL
preparation
protocol
1. Weigh out sufficient powder of each required AA for the batch size.
2. With the mixer running at high speed add required parts of each of the AA powders in turn until all materials are added to the suspensionh
n
t
f
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Frontiers in Psychiatry | www.frontiersin.org 4beverage composition is included, including excipients. Table 1
also shows AAs that comprise the BAL mixture, which differs
from the ATD mixture only with the addition of the AA L-TRP.
The final beverage composition is also included. Specific
manufacturing, packaging, and storage details are also provided.Amino Acids Used in the Moja-De ATD
Mixture:
L-Phenylalanine
L-Phenylalanine (PHE) is an essential aromatic AA in humans
(provided by the diet/ood). PHE plays a key role in the
biosynthesis of other AAs, and is important in the structure
and function of many proteins and enzymes. PHE is converted
into tyrosine, which is used in the biosynthesis of dopamine and
norepinephrine neurotransmitters. PHE is an odorless white
crystalline powder, with a slightly bitter taste and a pH (1%
aqueous solution) of 5.4 to 6. It has a water solubility of 26900
mg/L at 25°C.
Leucine
Leucine (LEU) is one of nine essential AAs in humans (provided
by the diet/food). LEU is important for protein synthesis and
many metabolic functions. LEU contributes to regulation of
blood-sugar levels; growth and repair of muscle and bone
tissue; growth hormone production; and wound healing. LEU
is available in many foods and diets, and deficiency is rare. LEU is
an odorless white crystalline powder, with a water solubility of
21,500 mg/L at 25°C.
L-Isoleucine
L-Isoleucine (ILE) is one of nine essential AAs in humans
(present in dietary proteins). L-ILE is a branched-chain
aliphatic AA found in many proteins, and it is an isomer of
LEUCINE. ILE has diverse physiological functions, such as
assisting wound healing, detoxification of nitrogenous wastes,
stimulating immune function, and promoting secretion of
several hormones. Necessary for hemoglobin formation and
regulating blood sugar and energy levels, ILE is concentrated
in muscle tissues in humans. ILE is an odorless white crystalline
powder, with a bitter taste and a water solubility of 34,400 mg/L
at 25°C.
L-Methionine
L-Methionine (MET) is a further example of nine essential AAs in
humans (provided by the diet/food), MET is required for growth
and tissue repair. A sulphur-containing AA, MET improves the
tone and pliability of skin, hair, and strengthens nails. Involved in
many detoxifying processes, sulphur provided by MET protects
cells from pollutants, slows cell aging, and is essential for
absorption and bio-availability of selenium and zinc. MET
chelates heavy metals, such as lead and mercury, aiding their
excretion. It also acts as a lipotropic agent, and prevents excess fat
buildup in the liver.MET is a white crystalline powder with a faint
odor and sulphurous taste. It has a pH of (1% aqueous solution) of
5.6 to 6.1, and a water solubility of 56,600 mg/L at 25°C.TA
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Stewart et al. Investigating Central Nervous 5HT FunctionL-Valine
L-Valine (VAL) is an aliphatic and extremely hydrophobic
essential AA in humans related to LEU and found in many
proteins, mostly in the interior of globular proteins helping to
determine three-dimensional structure. A glycogenic AA, VAL
maintains mental vigor, muscle coordination, and emotional
calm. VAL is obtained from soy, cheese, fish, meats, and
vegetables, and VAL supplements are used for muscle growth,
tissue repair, and energy. VAL is a white crystalline powder, and
has a water solubility of 58,500 mg/L at 25°C.L-Threonine
L-Threonine (THR) is an essential AA in humans (provided by
food) and is an important residue of many proteins, such as
tooth enamel, collagen, and elastin. It is an important AA for the
nervous system, and also plays an important role in porphyrin
and fat metabolism and prevents fat buildup in the liver. THR is
a white crystalline powder, and has a water solubility of 97,000
mg/L at 25°C.L-Lysine
L-Lysine (LYS) is one of nine essential AAs in humans required
for growth and tissue repair, and is supplied by many foods and
diets, especially red meats, fish, and dairy products. LYS is a
colorless crystalline powder with a sweet/bitter taste. It has a
water solubility of 1,000,000 mg/L at 25°C.L-Tryptophan
L-Tryptophan (TRP) is the least plentiful of all 22 AAs and an
essential AA in humans (provided by the diet/food), TRP is found
in most proteins and a precursor of 5-HT. TRP is converted to 5-
hydroxy-tryptophan (5-HTP), which in turn is converted to 5-HT,
a neurotransmitter essential in regulating appetite, sleep, mood,
and pain. TRP is present in dairy products, meats, brown rice, fish,
and soybeans. TRP is an odorless white to slightly yellowish-white
crystalline powder, with a slightly bitter taste. It has a water
solubility of 13,400 mg/L at 25°C. A 1% solution in water has a
pH of 5.5 to 7.
In the administration of the ATD Moja-De Protocol, the
aqueous suspension is often administered to young people
following an overnight protein fast. The protein fast decreases
the dietary intake of TRP, and the LNAAs in the beverage
compete with endogenous TRP for uptake into the CNS over
the BBB. This subsequently leads to decreased substrate
availability for central nervous 5-HT synthesis for a short
period of time (approx. 5–7 h). In addition, the administered
AAs stimulate protein synthesis in the liver, which takes
additional TRP from plasma stores and also contributes to the
depletion. The BAL beverage consists of all eight AAs, and causes
no significant alteration in brain 5-HT synthesis, as supported by
research conducted in rodents (23).Frontiers in Psychiatry | www.frontiersin.org 5VALIDATION OF THE ATD MOJA-DE/BAL
BODY WEIGHT-ADAPTED PROTOCOL
Animal Models
There are two animal model studies that have successfully
validated the ATD Moja-De/BAL body weight adapted
protocol (23, 24). Biskup & colleagues (23) validated a refined
body weight adapted ATD protocol called Moja-De in two
strains of mice, while Sanchez & colleagues (24) examined the
neurochemical effects of three developed formulas (ATD Moja-
De for 5-HT, phenylalanine/tyrosine depletion or PTD for
dopamine (DA) and a combined monoamine depletion
mixture or CMD) on brain 5-HT and DA function in mice.
Both studies concluded that the Moja-De protocol lowered brain
TRP and significantly decreased central nervous 5-HT synthesis.
Human Validation Studies
There are eight individual study sample populations that have
used the ATD Moja-De protocol across healthy and clinical
populations of adults and adolescents, and these have generated
other associated research papers (see Table 2). Given Moja-De’s
very likely changed side effect profile compared to other ATD
mixtures (which is presumably related to a lower concentration of
methionine and the administration of a body weight adjusted
ATD protocol and amount of AAs, as well as an overall reduced
total amount of AA’s), it is the only ATD protocol so far that has
been used in children and adolescents. Across these studies, the
ATD Moja-De protocol has been well tolerated overall, with
limited side effects/adverse events, and very few drop-outs in
studies. In addition, the body-weight-adjusted ATD protocol has
been proven to successfully lead to TRP depletion and a decreased
CNS of 5-HT, which has enabled Moja-De to be a valid tool to
explore the central nervous serotonergic system and related
aspects of TRP synthesis. Many of the studies using the Moja-
De ATD modification focused on ADHD or ADHD-related
symptoms. The following table summarises the findings so far.CONTRAINDICATIONS AND
SIDE EFFECTS
The ATD Moja-De protocol should be administered according to
the individual body weight, and the studies above demonstrate
safety, in addition to depletion-related efficacy and/or behavioral
effect-related efficacy (for example, effects on behavioral parameters
like reactive aggressive behaviors). The AAs contained in the ATD
and the BAL beverages are derived from a normal diet. The
beverages are contraindicated for use in participants with known
hypersensitivity to the active substance or any of the excipients, as
well as in participants with known changes in, or disorders of AA
metabolism and participants with psychotic features. Every use in
human populations needs to be carefully evaluated (risk vs. benefits
analysis) before the beverages are used.March 2020 | Volume 10 | Article 1007
Stewart et al. Investigating Central Nervous 5HT FunctionTABLE 2 | Summary of studies employing the ATD Moja-De Protocol in healthy and clinical populations (young people and adults).
Title Summary Subjects
Zepf (25) This thesis focused on aspects of reactive aggression in young patients with ADHD and
Moja-De ATD (aspects related to reactive aggression and Moja-De ATD were published
in publications 1A and 1C as listed below). This thesis also gives descriptive information
about other variables (heart rate, mood, verbal declarative memory, attentional
performance, etc.) that were obtained in this sample but were not part of the thesis
topic. These other variables were analyzed later (refer to articles 1C to 1I).
Final sample N = 22. N = 4 were excluded post-hoc after
having successfully completed the ATD and BAL challenge
protocols because of having received previous neuroleptic
medications. N = 5 refused to drink AA mixtures (one of these
patients was part of the N = 4 patients who had received
neuroleptic medications). N = 2 refused to participate in the
remaining study shortly after beverage intake.
Stadler et al.
(26)
This study used the ATD Moja-De protocol to study the impact of ATD on aggression in
children and adolescents with ADHD. The results indicated that children and adolescents
with ADHD behaved more aggressively after ATD when compared to BAL as assessed
using a point subtraction aggression game (a psychological task to assess reactive
aggression/impulsivity).
The data of N = 22 patients of the above-mentioned sample
were analyzed.
1B. Zepf
et al. (27)
This study examined the effects of ATD on reactive aggression as assessed with a Point
Subtraction Aggression Game (PSAG). ATD had a significant effect on increased
aggressive behavior with which low-grade impulsive patients responded. High-grade
impulsive patients were not affected by ATD.
The data of N = 22 patients of the abovementioned sample
were analyzed.
1C. Zepf
et al. (5)
This study explored the effects of ATD and the reduction of brain 5-HT synthesis on
behavioral inhibition in passive avoidance learning assessed in a computerized go/no-go
task.
The data of N = 22 patients of the above-mentioned sample
were analyzed.
1D. Zepf
et al. (28)
This study looked at differences in reaction times in the above-mentioned PSAG with
regard to the presence of the CBCL dysregulation profile (previously known as the CBCL
Paediatric Bipolar Disorder Profile, CBCL-PBD). Comparing those 6 patients with the
highest and clinically significant CBCL-PBD scores versus those 6 patients with the
lowest, patients with a high CBCL-PBD score showed a slower reaction time under RTD
compared to patients with low CBCL-PBD scores after high provocation.
N = 22 patients of the above-mentioned sample were
analyzed.
1E. Zepf
et al. (29)
Low impulsive patients showed a lower heart rate (HR) compared with placebo (those
were also patients behaving more aggressively after ATD administration, see paper
number 10). Diminished 5-HT functioning was associated with lowered HR.
N = 16 patients of the above-mentioned sample were
analyzed.
1F. Zepf
et al. (30)
This study looked at mood changes after ATD administration when compared to a
control condition. ATD had no clear effect on mood. Low scorers on baseline
venturesomeness were more strongly affected by ATD in terms of feelings of inactivity
and negative feelings compared to high baseline venture patients.
N = 17 patients of the above-mentioned sample were
analyzed.
1G. Zepf
et al. (31)
This study investigated the effects of ATD on attentional performance in children and
adolescents with ADHD. Lapses of attention (LA) and phasic alertness (PA) were
assessed within the test battery for attentional performance under depleted and sham-
depleted conditions 120 (T1), 220 (T2), and 300 (T3) min after intake of ATD or a
balanced control condition (BAL). At T1 there was a significant main effect for ATD,
indicating more LA after BAL intake compared to ATD. For T2/T3 there were no such
effects. PA was not affected by the factors ATD/BAL and time.
N = 22 patients of the above-mentioned sample were
analyzed.
1H. Zepf
et al. (4)
The aim of this study was focus on the participants’ opponent ratings when participating
in the PSAG while subjected to ATD and BAL AA mixtures. Following ATD intake, boys
with low aggression showed significantly higher extraversion ratings of their fictitious
opponent in the PSAG compared to boys with high aggression compared to the control
condition.
N = 22 patients of the above-mentioned sample were
analyzed.
1I. Zepf
et al. (6)
The aim of this study was to explore the effects of ATD Moja-De on memory function in
young males with attention deficit hyperactivity disorder (ADHD). Overall, there were no
significant effects of ATD administration on verbal declarative memory function.
N = 22 patients of the above-mentioned sample were
analyzed.
2A. Kötting
et al. (11)
This study aimed to analyze the effects of ATD on reactive aggression. Boys were more
likely to respond with an increased aggressive response after high provocation under
ATD. Girls had a higher relative risk than boys of an increased point subtraction in a
point subtraction aggression game under ATD after having received a low provocation.
N = 20 young people aged 9 - 15 years (10 female/10 male)
with ADHD.
2B. von
Polier et al.
(32)
Here the focus was to study impact of ATD on physiological arousal in 15 young people
with ADHD participating in an aggression-inducing game. ATD was not associated with
altered physiological arousal, as indexed by electrodermal activity (EDA). Baseline
aggression was negatively correlated with the mean ATD effect on EDA. In accordance
with the low arousal theory related to aggressive behavior, subjects with reduced
physiological responsiveness/lower electrodermal reactivity to ATD tended to display
elevated externalizing behavior.
N = 15 young people aged 9 - 15 years (8 female/7 male) with
ADHD (a sub-sample of the group studied in the paper by
Kötting et al., 2013, study number 2A in this table).
3A. Biskup
et al. (10)
Alterations of the default mode network (DMN), a network of several brain areas active
during rest, have been described in patients with neuropsychiatric disorders, including
ADHD. Male children and adolescents with ADHD and healthy controls were subjected
to the ATD Moja-De protocol. Three hours after the challenge intake (ATD or balanced
N = 22 males (12 – 17 years); 12 with ADHD and 10
neurotypical controls.
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Stewart et al. Investigating Central Nervous 5HT FunctionThe known side effects of acute ATD Moja-De are mild and
short-lived and include an unpleasant taste, nausea, and/or
vomiting (22) and lowered mood (27). These are expected to
be transient but nevertheless, clear risk mitigation strategies
should be in place, such as the administration of a TRP
replacement meal following the ATD Moja-De protocol.DISCUSSION
ATD protocols other than Moja-De have been used to investigate
central nervous 5-HT function of healthy subjects and across a
range of diverse clinical populations, particularly in adults (39).
The ATDMoja-De protocol was adapted from the seven AA ATD
mixture formulated by Moja et al. to account for the individual’sFrontiers in Psychiatry | www.frontiersin.org 7body weight (20), and theMoja-De AAmixture also contains AA’s
with a high affinity to the L-1 transporter at the BBB, thus allowing
efficient competitive antagonism with regards to central nervous
TRP uptake. This relatively new ATD protocol indirectly accounts
for baseline levels of TRP, the precursor for central nervous 5-HT.
Additionally, the Moja-De protocol contains a lower amount of
methionine (which contains sulphur) and also an overall smaller
amount of AA’s compared to other ATD protocols, and this has
likely reduces side-effects such as vomiting and nausea (21).
Combined, adjusting for body weight, reducing the overall
amount of AAs, and reducing methionine levels has led to the
development of a safe and effective neurochemical challenge
procedure for the use in young people.
Administration of the ATD Moja-De protocol in both animal
and human models of neuropsychiatric disorders have consistentlyTABLE 2 | Continued
Title Summary Subjects
control condition, BAL) resting state fMRI scans were obtained. The data indicated that
ATD was possibly beneficial to neural planning of motor activity.
4A.
Dingerkus
et al. (21)
This study investigated the effects of diminished central nervous system 5-HT synthesis
on plasma concentrations of relevant AAs using the ATD Moja-De protocol. ATD
decreased TRP-influx into the brain and CNS 5-HT synthesis safely and effectively and
was well tolerated, allowing it to be used in children and adolescents.
N = 24 healthy subjects aged 21 – 30 (N = 12 males and N =
12 females); within-subject repeated measures design with 2
measurement days per subject.
4B. Gaber
et al. (33)
This study investigated the effects of the Moja-De ATD protocol on punishment-related
behavioral inhibition. The results suggested that neurodietary challenges with ATD Moja-
De have no clear detrimental effects on task performance and punishment-related
inhibition in healthy adults.
See above (same sample as study 4A in this table).
5A.
Helmbold
et al. (34)
This study investigated the effects of diminished CNS 5-HT synthesis via the Moja-De
ATD protocol on verbal declarative episodic memory while controlling for the effects of
female sex hormones. The results indicated that in young women, verbal short-term
memory function was more vulnerable to ATD than consolidative processes.
N = 18 healthy female subjects aged 20 – 31 years; within-
subject repeated measures design with 2 measurement days
per subject
5B.
Helmbold
et al. (35)
This study investigated punishment-induced inhibition in healthy young women while
controlling for the menstrual cycle. Following administration of an ATD/balanced control
condition (BAL) challenge, neural activity was recorded during a reward or punishment
task using fMRI. The results suggested a serotonergic modulation of neural circuits
related to emotion regulation, impulse behavior, and punishment in females.
See above (same sample as study 5A in this table).
5C.
Helmbold
et al. (36)
This study examined the serotonergic modulation of intrinsic functional connectivity (FC)
with the default mode network (DMN) as assessed with fMRI, while controlling for the
menstrual cycle. The results indicated that ATD compared with balanced control
condition (BAL) significantly reduced FC with the DMN in areas of the brain associated
with self-referential thinking and enhanced FC in areas associated with cognitive
reasoning.
See above (same sample as study 5A in this table).
6A.
Hildebrand
et al. (37)
This study investigated the impact of short-term reductions in central nervous system
(CNS) 5-HT and dopamine (DA) synthesis via an adapted amino acid mixture
(phenylalanine-tyrosine depletion, PTD) on phasic alertness (a specific aspect of
attention) in healthy adults. The results support an association between decreased CNS
DA synthesis and slower reactions times, in line with previous research.
N = 50 healthy adult subjects (25 females, 26 males),
between-subject design (ATD: N = 16, PTD: N = 17, BAL: N =
17).
7A.
Zimmerman
et al. (9)
The study examined the effects of the ATD Moja-De protocol on reactive aggression.
Lowered rates of reactive aggression were found in the ADHD group under ATD after
low provocation, with controls showing the opposite effect.
N = 40 adult subjects (N = 20 with ADHD and N = 20 healthy
controls), within-subject repeated measures design.
7B.
Grabemann
et al. (38)
This study aimed to investigate whether diminished brain 5-HT synthesis via ATD can
impair the processing of affective prosody (the emotional tone of language) in adults with
ADHD. The results indicated that there was no clear evidence that 5-HT was implicated
in accurately processing affective prosody.
See above.
7C. Mette
et al. (12)
The study investigated the effects of ATD and the resulting reduction in CNS 5-HT
synthesis on discrimination ability and sustained attention. The results support the
contribution of serotonergic neurotransmission to attentional processes.
See above.
8A.
Demisch
et al. (15)
This study examined the relationship between body weight and dose effect of ATD with
an aim to standardize the ATD methodology. The results suggested that a body weight
adapted ATD-test Moja-De protocol that contained a greater amount of phenylalanine
(PHE) at the expense of tyrosine, appeared to be a suitable model for standardization of
ATD studies.
N = 14 healthy adult volunteers (N = 7 females and N = 7
males), within-subject repeated design.March 2020 | Volume 10 | Article 1007
Stewart et al. Investigating Central Nervous 5HT Functiondemonstrated lowered brain TRP and significantly decreased
central nervous 5-HT synthesis. Given this, the ATD Moja-De
protocol can be further extended and applied to investigate central
nervous 5-HT functioning in related neuropsychiatric disorders as
well as behavioral, physiological, and neuropsychological processes
in young people. A specific example includes the ATD Moja-De
protocol being employed as a method to investigate predictors of
treatment response to selective serotonin reuptake inhibitor (SSRI)
administration in adolescents with major depressive disorder (22).ETHICS STATEMENT
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